Outlook Therapeutics closes $33.1M convertible note, increases authorized shares to 260M

Outlook Therapeutics, Inc.

Issued $33.1M convertible note to Avondale Capital on March 13, 2025; proceeds used to repay $32.91M Streeterville note.
Stockholders approved increase in authorized common shares from 60M to 260M, effective March 11.
Annual Meeting elected directors: Julian Gangolli, Ralph Thurman, Lawrence Kenyon to Class III.
Stockholders approved potential issuance of >19.99% of outstanding common stock upon note conversion.
Ratified KPMG as auditor for FY2025; advisory say-on-pay passed.

item 1.02 item 5.03 item 5.07 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001558370-25-003013
form_type: 8-K
ticker: OTLK
cik: 0001649989
company_name: Outlook Therapeutics, Inc.
filed_at: 2025-03-14T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.307964+00:00
generated_at: 2026-05-24T18:34:19.396591+00:00
sec_items: ["1.02", "5.03", "5.07", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001558370-25-003013
json_url: https://secwatch.observer/filing/0001558370-25-003013.json
markdown_url: https://secwatch.observer/filing/0001558370-25-003013.md
text_url: https://secwatch.observer/filing/0001558370-25-003013.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/0001558370-25-003013-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/otlk-20250311x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001558370-25-003013

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.